PCM
DALS

Prelude Capital Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Prelude Capital Management’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55,275
Closed -$542K – 2398
2021
Q4 		$542K Hold
55,275
– – 0.01% 959
2021
Q3 		$543K Buy
+55,275
New +$546K 0.01% 848

Other funds holding DALS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's DALS Position: Q1 2022 in Review

Prelude Capital Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q1 2022, closing a stake of 55,275 shares — an estimated $542K sold.

Prelude Capital Management first reported a position in DALS in Q3 2021 and held it in 2 quarters. The position peaked at $543K in Q3 2021. 44 funds tracked by Wall St. Rank hold DALS as of Q1 2022.

  • Prelude Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
  • Prelude Capital Management sold 55,275 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q1 2022, an estimated $542K.
  • Prelude Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 2 quarters.
  • Prelude Capital Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $543K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q1 2022.

Based on Prelude Capital Management's 13F filing for Q1 2022, filed 16 May 2022.